One of the most satisfying aspects of covering biotech as long as I have is the opportunity to report on the long arc of drug development, from start to finish. It’s not always pretty, and more often than not, it ends badly.

But KarXT, now Cobenfy, is one of those drug stories with a happy ending. I remember talking to Steven Paul in 2019 for a story about the phase 2 results, which were pretty remarkable. Paul was excited about what KarXT might mean for people with schizophrenia, but he was cautious because, as he warned me at the time, clinical trials for psychiatric conditions are extraordinarily difficult to replicate. Let’s wait to see what KarXT does in Ph3 trials, he said.

Now, we know.

It’s been cool to follow and report on the KarXT story all these years. From PureTech to Karuna to Bristol Myers Squibb, and now, to

Keep reading this article on Marginal Revolution.